XOMA Announces Proposed Public Offering of Common Stock
December 12 2013 - 4:05PM
XOMA Corporation (Nasdaq:XOMA) announced today it is offering to
sell, subject to market and other conditions, shares of its common
stock pursuant to an effective shelf registration statement in an
underwritten public offering. XOMA also expects to grant the
underwriters a 30-day option to purchase up to an additional 15
percent of the shares of common stock offered in the public
offering.
Credit Suisse Securities (USA) LLC and Jefferies LLC are acting
as joint book running managers. The shares of common stock will be
issued pursuant to a prospectus supplement filed as part of a shelf
registration statement previously filed with the Securities and
Exchange Commission (SEC) on Form S-3.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. This press release is being issued pursuant to and in
accordance with Rule 134 under the Securities Act of 1933, as
amended. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of
the effective registration statement. Copies of the prospectus
supplement and accompanying prospectus relating to the offering may
be obtained from Credit Suisse Securities (USA) LLC, Attention:
Prospectus Department, One Madison Avenue, New York, NY 10010, by
telephone at 800-221-1037, or by email at
newyork.prospectus@credit-suisse.com, or from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12th Floor, New York, NY 10022, by telephone at
877-547-6340, or by email at prospectus_department@jefferies.com.
XOMA intends to file a final prospectus supplement relating to the
offering with the SEC, which will be available along with the
accompanying prospectus filed with the SEC in connection with the
shelf registration, on the SEC's website at http://www.sec.gov.
About XOMA
XOMA discovers and develops innovative antibody
therapeutics.
Forward-Looking Statements
Certain statements contained in this press release including,
but not limited to, statements related to anticipated completion
and timing of the proposed public offering are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements are based on assumptions that may not prove
accurate. Actual results could differ materially from those
anticipated due to certain risks and uncertainties including,
without limitation, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related
to the public offering. There can be no assurance that XOMA will be
able to complete the public offering on the anticipated terms, or
at all. Risks and uncertainties relating to XOMA and its business
can be found in the "Risk Factors" section of XOMA's most recent
filing on Form 10-Q for the quarter ended September 30, 2013 and in
the preliminary prospectus supplement related to the proposed
offering to be filed with the SEC on or about the date hereof..
Consider such risks carefully when considering XOMA's prospects.
Any forward-looking statement in this press release represents
XOMA's views only as of the date of this press release and should
not be relied upon as representing its views as of any subsequent
date. XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
CONTACT: XOMA Corporation
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024